FN2 Earnings Intelligence
Teva Pharmaceutical Industries Limited ratios (quarterly)
Teva Pharmaceutical Industries Limited (TEVA) Ratios (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $1,697 | $2,161 | $2,203 | $3,741 | $3,655 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | $3,891 | $4,176 | $4,480 | $3,982 | $4,142 |
| % Growth | - | - | - | - | - |
| Gross Profit | $1,877 | $2,102 | $2,304 | $1,972 | $2,153 |
| % Margin | 48.2% | 50.3% | 51.4% | 49.5% | 52.0% |
| EBITDA | $763 | $706 | $1,131 | $891 | $10 |
| % Margin | 19.6% | 16.9% | 25.2% | 22.4% | 0.2% |
| Net Income | $214 | $282 | $433 | $369 | -$576 |
| % Margin | 5.5% | 6.8% | 9.7% | 9.3% | -13.9% |
| Diluted EPS | $0.18 | $0.24 | $0.37 | $0.31 | -$0.49 |
| % Growth | - | - | - | - | - |
| Operating Cash Flow | -$105 | $227 | $369 | -$40 | $411 |
| CapEx | $127 | $96 | $136 | $168 | $104 |
| Free Cash Flow | -$232 | $131 | $233 | -$208 | $307 |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue | $3,891 | $4,176 | $4,480 | $3,982 | $4,142 |
| Gross Profit | $1,877 | $2,102 | $2,304 | $1,972 | $2,153 |
| EBITDA | $763 | $706 | $1,131 | $891 | $10 |
| Net Income | $214 | $282 | $433 | $369 | -$576 |
| Diluted EPS | $0.18 | $0.24 | $0.37 | $0.31 | -$0.49 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1,697 | $2,161 | $2,203 | $3,741 | $3,655 |
| Short-term Debt | $421 | $464 | $24 | $2,612 | $23 |
| Long-term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$105 | $227 | $369 | -$40 | $411 |
| Capital Expenditure | $127 | $96 | $136 | $168 | $104 |
| Free Cash Flow | -$232 | $131 | $233 | -$208 | $307 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 48.2% | 50.3% | 51.4% | 49.5% | 52.0% |
| EBITDA Margin | 19.6% | 16.9% | 25.2% | 22.4% | 0.2% |
| Net Margin | 5.5% | 6.8% | 9.7% | 9.3% | -13.9% |
| FCF Margin | -6.0% | 3.1% | 5.2% | -5.2% | 7.4% |
| Diluted EPS Growth | - | - | - | - | - |
Get the TEVA recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.